Skip to main content
. 2024 Jun 2;29(11):2616. doi: 10.3390/molecules29112616

Figure 3.

Figure 3

Selectivity of compound 62 against a panel of selected CMGC kinases (CDK1, CDK2, CDK4, CDK6, CDK7, CDK9, DYRK1A, DYRK1B, GSK-3α, GSK-3β, JNK2α2, JNK3, MAPK1, MAPK2, SAPK2a, SAPK2b, and SAPK3). The data are presented as the percentage of kinase inhibition at a concentration of 1 μM of inhibitor 62.